Evaluation of GenoType NTM-DR Assay for Identification of Mycobacterium chimaera

Mok, Simone; Rogers, Thomas R.; Fitzgibbon, Margaret

doi:10.1128/jcm.00009-17

Cited by 22 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two commercial kitsdINNO-LiPA Mycobacteria and GenoType NTM-DRdcompared well with the reference sequencing, but GenoType Mycobacterium CM and MALDI-TOF MS were not able to sufficiently discriminate M. intracellulare from M. chimaera. These results were in accordance with a recent description of GenoType NTM-DR being tested on 173 MAC isolates from Ireland with a 91% agreement with ITS sequencing [23]. Mass spectrometry was generally disappointing for precise identification of nontuberculous mycobacteria [20,24].…”

Section: Discussionsupporting

confidence: 89%

Comparison of methods available for identification of Mycobacterium chimaera

Lecorché

Haenn

Mougari

et al. 2018

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives: Mycobacterium chimaera is a recently described nontuberculous mycobacterium belonging to the Mycobacterium avium complex (MAC). Because this species is implicated in a worldwide outbreak due to contaminated heaterecooler unit water tanks during open-heart surgery, it has become mandatory for clinical microbiology laboratories to be able to differentiate M. chimaera from the other MAC species, especially M. intracellulare. Such identification has so far been restricted to specialized laboratories because it required the analysis of several gene sequences. The aim of this study was to evaluate commercial methods for identifying M. chimaera with regard to the reference gene sequencing ITS, the internal transcribed spacer 16e23S. Methods: Forty-seven clinical and environmental isolates including 41 MAC were identified by (a) PCR sequencing of the ITS and hsp65 genes, (b) three molecular biology kits (INNO-LiPA Mycobacteria, GenoType Mycobacterium CM and GenoType NTM-DR) and (c) matrix-assisted desorption ionizatione time of flight mass spectrometry (MALDI-TOF MS) using Microflex LT. Results: There was a high concordance for species determination between the reference ITS sequencing and the GenoType NTM-DR test (39/41, 95%), the INNO-LiPA Mycobacteria test (38/41, 93%) and the hsp65 sequencing (38/41, 93%). The GenoType Mycobacterium CM test did not distinguish M. chimaera from M. intracellulare. MALDI-TOF MS distinguished two M. chimaeraeM. intracellulare groups separated from M. avium and from the other mycobacterial species on a score-oriented dendrogram, but it also failed to differentiate the two species. Conclusions: INNO-LiPA Mycobacteria and GenoType NTM-DR are efficient assays for M. chimaera identification in clinical microbiology laboratories.

show abstract

Section: Discussionsupporting

confidence: 89%

Comparison of methods available for identification of Mycobacterium chimaera

Lecorché

Haenn

Mougari

et al. 2018

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…M. chimaera isolates (n ϭ 87) included an archival collection collected between 2007 and 2017 and more recent clinical and environmental isolates referred from Irish hospitals to the Irish Mycobacteria Reference Laboratory in St. James Hospital, Dublin, Ireland. All isolates were identified by sequencing the 16S rRNA gene and internal transcribed spacer (ITS) region, and a subset of isolates were also identified using the GenoType NTM-DR v1.0 assay (Hain Lifescience), as described previously (42). M. chimaera isolates included for AST were selected on the basis of 1 isolate per patient per year.…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates

Mok

Hannan

Nölke

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Mycobacterium chimaera is a slow-growing nontuberculous Mycobacterium species belonging to the Mycobacterium avium complex (MAC). It has been identified globally as the cause of a large outbreak of cardiovascular infections following open heart surgery, but it can also cause respiratory infections in individuals with underlying structural pulmonary disease. Invasive M. chimaera infections are associated with poor clinical responses, and the optimal antibiotic treatment regimen for these infections is not known. In this study, the drug susceptibility profiles of clinical and environmental M. chimaera isolates for antimicrobial agents that are commonly considered for treatment of MAC infections were determined. All M. chimaera isolates were susceptible to clarithromycin, with a median MIC of 2 μg/ml, while 98% (85/87 isolates) were susceptible to amikacin. Twenty-five percent of isolates (22/87 isolates) had intermediate susceptibility and 52% (46/87 isolates) were resistant to moxifloxacin. Similarly, 39% of isolates (34/87 isolates) had intermediate susceptibility and 39% (34/87 isolates) were resistant to linezolid. MIC breakpoints derived from the literature were used to determine resistance to rifampin (16/87 isolates [18%]), ethambutol (10/87 isolates [11%]), rifabutin (2/87 isolates [2%]), and streptomycin (1/87 isolates [1%]). In conclusion, our results showed that clarithromycin, amikacin, rifabutin, and streptomycin had the best activity against M. chimaera isolates, while susceptibility rates were lower for rifampin and ethambutol. In contrast, there was a high prevalence of isolates that were not susceptible to moxifloxacin or linezolid. While factors in addition to antibiotic susceptibility may determine the outcomes of treatment of M. chimaera infections, our results should inform the selection of antimicrobials as part of the overall therapeutic strategy.

show abstract

“…Schweickert et al [9] reported that in Germany almost 86% of previously identified species as M. intracelullare are actually M. chimaera. Mok et al [4] reported data from Ireland where 55% of M. intracelullare isolates were misidentified and are actually M. chimaera. Our study showed that M. intracelullare was more often clinically relevant than M. chimaera (29% vs. 6% of clinical isolates, respectively).…”

Section: Resultsmentioning

confidence: 99%

“…During surgeries, HCUs produce aerosols and M. chimaera is dispersed into the air and can colonize the patient. Due to M. chimaera's slowgrowth, it can take even several years after surgery to develop disease [4,8].…”

Section: Introductionmentioning

confidence: 99%

“…The aim of our study was to perform a retrospective analysis of all Slovenian MAC and MABSC isolates with new molecular test GenoType NTM-DR, which is known to successfully identify M. chimaera isolates and also enables mutation identification in rrl, rrs and erm(41) genes [2,4]. Our purpose was therefore to identify how many M. chimaera isolates were misidentified as M. intracellulare and to estimate how many isolates are resistant to macrolides and aminoglycosides and which mutations are prevalent in Slovenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Analysis of Slovenian Mycobacterium Avium Complex and Mycobacterium Abscessus Complex Isolates and Molecular Resistance Profile

Truden

Жолнир-Довч

Содья

et al. 2018

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Abstract. Mycobacteria belonging to Mycobacterium (M.) avium complex (MAC) and M. abscessus complex (MABSC) are the most frequent causes of mycobacteriosis in the world. In the last few years MAC and MABSC taxonomy was rapidly changing due to new molecular methods conveying the possibility to differentiate between species. New techniques are able to identify M. chimaera that was previously recognized as M. intracellulare and also differentiate subspecies of MABSC. Due to their natural habitat, non-tuberculous mycobacteria (NTM) are constantly exposed to various concentrations of antimicrobial drugs and other chemicals and consequently they had developed different mechanisms of resistance. Macrolides and aminoglycosides are frequently used drugs to treat MAC and MABSC infections. The aim of our nation-wide survey was to obtain information about MABSC subspecies prevalence in Slovenia and to assess the percentage of misidentifications of M. chimaera isolates as M. intracellulare in the past. Moreover, the purpose of our study was to reveal, which of the two species M. intracellulare or M. chimaera is clinically more relevant in Slovenia. Further, the aim of the study was to detect mutations in erm(41), rrl and rrs genes, which are known to convey macrolide resistance (erm(41) and rrl) and aminoglycoside resistance (rrs). One hundred and thirty-two Slovenian mycobacterial isolates obtained from the National Mycobacterial Collection that belong to MAC and MABSC were analysed. GenoType NTM-DR was used to differentiate M. intracellulare from M. chimaera and subspecies of MABSC. Our results showed that 48% of previously identified M. intracellulare isolates were actually M. chimaera isolates and that M. abscessus subsp. abscessus was the most frequent subspecies of MABSC. Most of the MABSC isolates carried the inducible macrolide resistance genes (erm(41) and rrl), however none of the isolates of MAC and MABSC had mutations in rrs genes for aminoglycoside resistance.

show abstract

Evaluation of GenoType NTM-DR Assay for Identification of Mycobacterium chimaera

Cited by 22 publications

References 25 publications

Comparison of methods available for identification of Mycobacterium chimaera

Comparison of methods available for identification of Mycobacterium chimaera

Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates

Retrospective Analysis of Slovenian Mycobacterium Avium Complex and Mycobacterium Abscessus Complex Isolates and Molecular Resistance Profile

Contact Info

Product

Resources

About